Ratings Fuso Pharmaceutical Industries,Ltd.

Equities

4538

JP3823600006

Delayed Japan Exchange Other stock markets 08:50:39 2024-05-01 pm EDT			5-day change	1st Jan Change
2,238 ^JPY	-0.40%		+1.22%	+18.35%

2023	Tranche Update on Fuso Pharmaceutical Industries,Ltd.'s Equity Buyback Plan announced on September 5, 2023.	CI
2023	Fuso Pharmaceutical Industries,Ltd.'s Equity Buyback announced on September 5, 2023, has closed with	CI

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company benefits from high valuations in earnings multiples.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
FUSO PHARMACEUTICAL INDUSTRIES,LTD.	+18.35%	120M	-	-
ELI LILLY AND COMPANY	+33.25%	704B		C+
NOVO NORDISK A/S	+28.59%	577B		B
JOHNSON & JOHNSON	-3.55%	348B		C+
MERCK & CO., INC.	+18.16%	327B		B-
ABBVIE INC.	+4.36%	288B		C+
ASTRAZENECA PLC	+14.81%	234B		B+
NOVARTIS AG	+4.93%	198B		B-
ROCHE HOLDING AG	-9.78%	194B		A+
AMGEN INC.	-3.69%	147B		C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes